Expanding the clinical and metabolic phenotype of DPM2 deficient congenital disorders of glycosylation.

[1]  Jiewen Zhang,et al.  Novel mutations in DPM3 cause dystroglycanopathy with central nervous system involvement , 2019, Clinical genetics.

[2]  T. Shima,et al.  Endoplasmic reticulum stress disrupts lysosomal homeostasis and induces blockade of autophagic flux in human trophoblasts , 2019, Scientific Reports.

[3]  N. Romero,et al.  Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene , 2019, Neuromuscular Disorders.

[4]  E. Morava,et al.  A novel phosphoglucomutase‐deficient mouse model reveals aberrant glycosylation and early embryonic lethality , 2019, Journal of inherited metabolic disease.

[5]  D. Cassiman,et al.  The Metabolic Map into the Pathomechanism and Treatment of PGM1-CDG. , 2019, American journal of human genetics.

[6]  C. Pérez-Cerdá,et al.  Clinical and molecular diagnosis of non‐phosphomannomutase 2 N‐linked congenital disorders of glycosylation in Spain , 2019, Clinical genetics.

[7]  D. Lefeber,et al.  Toward understanding tissue‐specific symptoms in dolichol‐phosphate‐mannose synthesis disorders; insight from DPM3‐CDG , 2019, Journal of inherited metabolic disease.

[8]  Ellen F. Macnamara,et al.  A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation. , 2018, American journal of human genetics.

[9]  T. Pulinilkunnil,et al.  Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature , 2017, Journal of Inherited Metabolic Disease.

[10]  G. Matthijs,et al.  Galactose Supplementation in Patients With TMEM165-CDG Rescues the Glycosylation Defects , 2017, The Journal of clinical endocrinology and metabolism.

[11]  Dae-Young Lee,et al.  UPLC-QqQ/MS-Based Lipidomics Approach To Characterize Lipid Alterations in Inflammatory Macrophages. , 2017, Journal of proteome research.

[12]  M. Lek,et al.  A homozygous DPM3 mutation in a patient with alpha-dystroglycan-related limb girdle muscular dystrophy , 2016, Neuromuscular Disorders.

[13]  J. Cardinal,et al.  DMP1-CDG (CDG1e) with Significant Gastrointestinal Manifestations; Phenotype and Genotype Expansion. , 2016, JIMD reports.

[14]  Akhilesh Pandey,et al.  PyQuant: A Versatile Framework for Analysis of Quantitative Mass Spectrometry Data* , 2016, Molecular & Cellular Proteomics.

[15]  G. Matthijs,et al.  Glycosylation abnormalities in Gdt1p/TMEM165 deficient cells result from a defect in Golgi manganese homeostasis. , 2016, Human molecular genetics.

[16]  Y. Yung,et al.  Lysophosphatidic acid signalling in development , 2015, Development.

[17]  R. Naeije,et al.  Possible Role of Lysophosphatidic Acid in Rat Model of Hypoxic Pulmonary Vascular Remodeling , 2014, Pulmonary circulation.

[18]  G. Schmitz,et al.  Sphingolipids in Human Synovial Fluid - A Lipidomic Study , 2014, PloS one.

[19]  K. Campbell,et al.  Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy. , 2013, Molecular genetics and metabolism.

[20]  E. Bertini,et al.  DPM2‐CDG: A muscular dystrophy–dystroglycanopathy syndrome with severe epilepsy , 2012, Annals of neurology.

[21]  H. Freeze,et al.  Identification of Intercellular Cell Adhesion Molecule 1 (ICAM-1) as a Hypoglycosylation Marker in Congenital Disorders of Glycosylation Cells* , 2012, The Journal of Biological Chemistry.

[22]  J. Hofsteenge,et al.  Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. , 2009, American journal of human genetics.

[23]  C. Lawson,et al.  ICAM-1 signaling in endothelial cells , 2009, Pharmacological reports : PR.

[24]  Athanasia Spandidos,et al.  A comprehensive collection of experimentally validated primers for Polymerase Chain Reaction quantitation of murine transcript abundance , 2008, BMC Genomics.

[25]  Y. Maeda,et al.  Dolichol-phosphate mannose synthase: structure, function and regulation. , 2008, Biochimica et biophysica acta.

[26]  E. Eskelinen.  Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. , 2006, Molecular aspects of medicine.

[27]  I. Sfaello,et al.  A New Intronic Mutation in the DPM1 Gene Is Associated With a Milder Form of CDG Ie in Two French Siblings , 2006, Pediatric Research.

[28]  T. Hennet,et al.  Congenital disorder of glycosylation (CDG) type Ie. A new patient , 2004, Journal of Inherited Metabolic Disease.

[29]  A. Witkowska,et al.  Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. , 2004, European cytokine network.

[30]  B. Giepmans,et al.  Lysophosphatidic acid: mitogen and motility factor. , 2003, Biochemical Society transactions.

[31]  K. von Figura,et al.  Role of LAMP-2 in lysosome biogenesis and autophagy. , 2002, Molecular biology of the cell.

[32]  E. Berger,et al.  Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie. , 2000, The Journal of clinical investigation.

[33]  H. Freeze,et al.  Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie) , 2000, The Journal of clinical investigation.

[34]  A. Bhunia,et al.  Lactosylceramide Mediates Tumor Necrosis Factor-α-induced Intercellular Adhesion Molecule-1 (ICAM-1) Expression and the Adhesion of Neutrophil in Human Umbilical Vein Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[35]  H. G. van Eijk,et al.  The analysis of human serum transferrins with the PhastSystem: Quantitation of microheterogeneity , 1992, Electrophoresis.